Safety and performance of targeted renal therapy: The Be-RITe! registry

Giora Weisz, Steven J. Filby, Mauricio G. Cohen, David E. Allie, Barry S. Weinstock, Dimitris Kyriazis, Craig M. Walker, Jeffrey W. Moses, Paolo Danna, William F. Fearon, Naveen Sachdev, Bret N. Wiechmann, Kishor Vora, Laura Findeiss, Matthew J. Price, Roxana Mehran, Martin B. Leon, Paul S. Teirstein

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Purpose: To evaluate the safety and patterns of use of targeted renal therapy (TRT) with the Benephit system. TRT, the delivery of therapeutic agents directly to the kidneys by renal arterial infusion, has the advantage of providing a higher local effective dose with potentially greater renal effects, while limiting systemic adverse effects due to renal first-pass elimination. Methods: The Benephit System Renal Infusion Therapy (Be-RITe!) Multicenter Registry was a post-market registry following patients treated using the Benephit systems for TRT. The registry enrolled 501 patients (332 men; mean age 72.2±9.5 years) at high risk for contrast-induced nephropathy (CIN) during coronary or peripheral angiography/intervention or cardiovascular surgery. The Mehran score was used to compare the actual to predicted incidence of CIN within 48 hours post procedure. Results: Bilateral renal artery cannulation was successful in 94.2%, with a mean cannulation time of 2.0 minutes. Either fenoldopam mesylate, sodium bicarbonate, alprostadil, or B-type natriuretic peptide (BNP) was infused for 184±212 minutes. Mean creatinine levels did not change significantly (baseline, 24, and 48 hours post procedure: 1.95, 1.99, and 1.98 mg/dL, respectively; p=NS). In 285 patients who received TRT with fenoldopam and were followed for at least 48 hours, the incidence of CIN was 71% lower than predicted (8.1% actual CIN versus 28.0% predicted; p<0.0001). Only 4 (1.4%) patients required dialysis (versus the 2.6% predicted rate, p=NS). Conclusion: The Benephit system and TRT during coronary and endovascular procedures in patients at high risk for renal failure is simple to use and safe. With the infusion of intrarenal fenoldopam, the incidence of CIN was significantly lower than predicted by risk score calculations.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalJournal of Endovascular Therapy
Volume16
Issue number1
DOIs
StatePublished - Feb 2009
Externally publishedYes

Keywords

  • Contrast media
  • Contrast-induced nephropathy
  • Fenoldopam
  • Percutaneous intervention
  • Renal dysfunction
  • Targeted renal therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Safety and performance of targeted renal therapy: The Be-RITe! registry'. Together they form a unique fingerprint.

  • Cite this

    Weisz, G., Filby, S. J., Cohen, M. G., Allie, D. E., Weinstock, B. S., Kyriazis, D., Walker, C. M., Moses, J. W., Danna, P., Fearon, W. F., Sachdev, N., Wiechmann, B. N., Vora, K., Findeiss, L., Price, M. J., Mehran, R., Leon, M. B., & Teirstein, P. S. (2009). Safety and performance of targeted renal therapy: The Be-RITe! registry. Journal of Endovascular Therapy, 16(1), 1-12. https://doi.org/10.1583/08-2515.1